2 hours ago
1
georgeclerk
Rapport Therapeutics (NASDAQ:RAPP) traded higher on Friday after Goldman Sachs assigned the neurology drug developer a Buy rating and a 12-month price target of $51 based on mid-stage trial data the company recently disclosed for its antiseizure therapy RAP-219.
Shares
© FBT Company 2025. All rights are reserved
English (US) ·